Single platform femtosecond laser announced at ESCRS

Article

Bausch + Lomb and Technolas Perfect Vision have announced the release of the VICTUS femtosecond laser platform at this year's ESCRS meeting in Vienna, Austria.

Bausch + Lomb (B+L) and Technolas Perfect Vision (TPV) have announced the release of the VICTUS femtosecond laser platform that supports cataract, refractive and therapeutic procedures at this year’s ESCRS meeting in Vienna, Austria.

CEO and president of the Global Surgical Business for B+L, Robert E. Grant, commented on the news, stating, "Our focus is on bringing innovative products, like the VICTUS platform, to the market that uniquely benefit ophthalmic surgeons and patients. TPV's advanced German engineering and precise manufacturing are perfect complements to B+L's surgical portfolio."

The companies have announced that early clinical data on the platform will be presented at the upcoming AAO meeting in Orlando, Florida, USA and at the Asia-Pacific Association of Cataract and Refractive Surgeons in Seoul, South Korea. Additionally, both companies are currently working with regulatory authorities to secure marketing approvals and will promote the platform globally.

This news comes shortly after the recent announcement that B+L and TPV entered into a definitive agreement with an option for B+L to purchase all outstanding and not owned TPV shares.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.